Large Caps To Lead China’s Outbound Pharma M&A

China’s large-cap pharmaceutical groups have been actively scouting for overseas M&A deals in recent years, with the aims of acquiring advanced technology and bigger global market shares. These cash-rich players’ interest in outbound investment is set to remain high, experts predict.